Current Partners

NATIONAL CANCER INSTITUTE

PDS has an active Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the U.S. National Institutes of Health. Under the CRADA, PDS and NCI aim to co-develop several immunotherapies through several upcoming Phase II clinical trials in 2018 – 2020, utilizing combinations of Versamune® with NCI- and PDS-sourced tumor-related proteins or their fragments recognized by the immune system (antigens) in prostate, breast, and HPV-related cancers.

MERCK CIE/EMD MILLIPORE

Schaffhausen, Switzerland: A division of EMD-Millipore, Merck Cie, has developed a proprietary process to manufacture the patented structurally-specific lipid used in Versamune®. Merck Cie has granted PDS Biotechnology an exclusive worldwide commercial license to utilize the chiral lipid in immunotherapies and vaccines.  Merck Cie provides the lipid manufactured under cGMP conditions for use in PDS Biotechnology’s products.